Ascendis Pharma A/S
ASND163.242USD
-0.907-0.55%
Horário de mercado （ET）Cotações atrasadas em 15 min
9.90BValor de mercado
PerdaP/L TTM
Mais detalhes de Ascendis Pharma A/S Empresa
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Informações da empresa
Código da empresaASND
Nome da EmpresaAscendis Pharma A/S
Data de listagemJan 28, 2015
Fundado em2006
CEOMr. Jan Moller Mikkelsen
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscalJan 28
EndereçoTuborg Boulevard 12
CidadeHELLERUP
Bolsa de valoresNASDAQ Global Select Consolidated
PaísDenmark
Código postal2900
Telefone4570222244
Sitehttps://ascendispharma.dk/
Código da empresaASND
Data de listagemJan 28, 2015
Fundado em2006
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Mr. Mads Bodenhoff
Mr. Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Senior Vice President, Head of Finance and Principal Accounting Officer
193.00
--
Mr. Donovan (Jay) Wu
Mr. Donovan (Jay) Wu
Executive Vice President, U.S. President
Executive Vice President, U.S. President
--
--
Dr. Aimee Shu,, M.D.
Dr. Aimee Shu,, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Detalhamento da receita
Moeda: EURTempo de atualização: dom, 6 de abr
Moeda: EURTempo de atualização: dom, 6 de abr
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaEUR
Nome
Receita
Proporção
Commercial sale of products
55.71M
96.33%
Rendering of services
1.27M
2.20%
License
851.00K
1.47%
Sale of clinical supply
0.00
0.00%
Por RegiãoEUR
Nome
Receita
Proporção
North America
48.76M
84.31%
Europe
8.15M
14.09%
Asia
924.00K
1.60%
Rest of world
924.00K
1.60%
Por Empresa
Por Região
Por EmpresaEUR
Nome
Receita
Proporção
Commercial sale of products
55.71M
96.33%
Rendering of services
1.27M
2.20%
License
851.00K
1.47%
Sale of clinical supply
0.00
0.00%
Acionista
Tempo de atualização: sáb, 26 de abr
Tempo de atualização: sáb, 26 de abr
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
RA Capital Management, LP
16.66%
Westfield Capital Management Company, L.P.
9.11%
Avoro Capital Advisors LLC
8.41%
Artisan Partners Limited Partnership
7.33%
Janus Henderson Investors
7.22%
Other
51.27%
Estatísticas dos acionistas
Acionista
Proporção
RA Capital Management, LP
16.66%
Westfield Capital Management Company, L.P.
9.11%
Avoro Capital Advisors LLC
8.41%
Artisan Partners Limited Partnership
7.33%
Janus Henderson Investors
7.22%
Other
51.27%
Tipo
Acionista
Proporção
Investment Advisor/Hedge Fund
42.21%
Investment Advisor
39.31%
Hedge Fund
25.01%
Research Firm
2.54%
Individual Investor
0.78%
Family Office
0.44%
Family Office
0.44%
Family Office
0.44%
Venture Capital
0.38%
Participação acionária institucional
Tempo de atualização: seg, 20 de jan
Tempo de atualização: seg, 20 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
473
67.43M
111.11%
-2.45M
2024Q4
488
67.37M
111.00%
-7.76M
2024Q3
475
65.25M
107.66%
-6.23M
2024Q2
459
63.44M
108.94%
-9.21M
2024Q1
453
63.54M
109.13%
-8.68M
2023Q4
430
62.90M
109.00%
-9.55M
2023Q3
414
62.85M
109.61%
-11.90M
2023Q2
426
63.03M
109.93%
-13.27M
2023Q1
427
63.10M
110.08%
-9.14M
2022Q4
426
67.66M
118.40%
-4.66M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RA Capital Management, LP
10.11M
16.66%
+402.32K
+4.14%
Dec 31, 2024
Westfield Capital Management Company, L.P.
5.53M
9.11%
+394.47K
+7.68%
Dec 31, 2024
Avoro Capital Advisors LLC
5.10M
8.41%
+114.17K
+2.29%
Dec 31, 2024
Artisan Partners Limited Partnership
4.45M
7.33%
+39.31K
+0.89%
Dec 31, 2024
Janus Henderson Investors
4.38M
7.22%
+193.69K
+4.63%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.36M
7.18%
-196.51K
-4.32%
Dec 31, 2024
Capital International Investors
2.86M
4.72%
+753.86K
+35.74%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
2.73M
4.49%
+960.50K
+54.42%
Dec 31, 2024
T. Rowe Price Associates, Inc.
2.28M
3.76%
+162.08K
+7.64%
Dec 31, 2024
MFS Investment Management
1.86M
3.07%
-415.00
-0.02%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
Harbor Health Care ETF
16.1%
Virtus LifeSci Biotech Products ETF
1.93%
BNY Mellon Innovators ETF
1.85%
Tema Cardiovascular and Metabolic ETF
1.43%
American Century Focused Dynamic Growth ETF
1.43%
ProShares Ultra Nasdaq Biotechnology
0.94%
Invesco Nasdaq Biotechnology ETF
0.9%
JPMorgan Healthcare Leaders ETF
0.66%
iShares Biotechnology ETF
0.61%
Main Thematic Innovation ETF
0.61%
Ver Mais
Harbor Health Care ETF
Proporção16.1%
Virtus LifeSci Biotech Products ETF
Proporção1.93%
BNY Mellon Innovators ETF
Proporção1.85%
Tema Cardiovascular and Metabolic ETF
Proporção1.43%
American Century Focused Dynamic Growth ETF
Proporção1.43%
ProShares Ultra Nasdaq Biotechnology
Proporção0.94%
Invesco Nasdaq Biotechnology ETF
Proporção0.9%
JPMorgan Healthcare Leaders ETF
Proporção0.66%
iShares Biotechnology ETF
Proporção0.61%
Main Thematic Innovation ETF
Proporção0.61%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados